VIVUS Announces Scientific Presentations

MOUNTAIN VIEW, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- VIVUS,Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing Qsymia ® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today announced the following scientific presentations in connection with Obesity Week 2013:

Pre-Conference

Early Development Pharmacologic and Device Session for Up and Coming Obesity Treatments

Date/Time

Tuesday, November 12, 2013, 12:00 pm - 1:30 pm

Georgia World Congress Center, Room A404-A405

Conference

Obesity Week 2013: First Annual Obesity Week: A collaboration of the American Society for Metabolic & Bariatric Surgery (ASMBS) and The Obesity Society (TOS)

November 11-16, 2013

Georgia World Congress Center, Atlanta, GA

Date/Time

Oral Presentation Date: November 14, 2013 from 3:00 PM to 4:30 PM

Session Location: Georgia World Congress Center, A404-A405

Abstract number: T-35-OR

Presentation Title

Depression and Weight Loss Over 2 Years in Obese and Overweight Subjects Receiving Phentermine and Topiramate Extended-Release

Authors: Patrick M. O'Neil, PhD a; Craig Peterson, MS b

Affiliations: aMedical University of South Carolina, Charleston, SC; bVIVUS, Inc., Mountain View, CA

Date/Time

Oral Presentation Date: Friday, November 15, 2013 from 4:30 to 4:45pm

Session Location: Georgia World Congress Center, A402-A403

Presentation Title

Evaluation of Phentermine and Topiramate vs. Phentermine/Topiramate Extended-Release in Obese Adults

Authors: Louis J. Aronne, MD a; Thomas A. Wadden, PhD b; Craig Peterson, MS c; David Winslow, MD d; Sarah Odeh, BS, CMPP c, and Kishore M. Gadde, MD e

Affiliations: aWeill Cornell Medical College, New York, NY; bPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA; cVIVUS, Inc., Mountain View, CA; dKentucky Research Group, Louisville, KY; eDuke University Medical Center, Durham, NC

Date/Time

Poster Presentation Date: November 14, 2013
  • Poster viewing: 10:00am - 3:30pm and 5:30pm - 7:00pm
  • Authors present posters: 5:30pm - 7:00pm

Session Location: Georgia World Congress Center, Exhibit Hall A

Poster Number: 33-LB-P

Presentation Title

Phentermine and Topiramate Extended-Release Is Effective for Weight Loss in a Diverse Population of Obese/Overweight Subjects

Authors: Robert F. Kushner, MD a; Michelle Look, MD b; Antoinette Stroh, BS c; Craig A. Peterson, MS c

Affiliations: aNorthwestern University Feinberg School of Medicine, Chicago, IL; bSan Diego Sports Medicine and Family Health Center, San Diego, CA; cVIVUS, Inc., Mountain View, CA

Date/Time

Poster Presentation Date: November 14, 2013
  • Poster viewing: 10:00am - 3:30pm and 5:30pm - 7:00pm
  • Authors present posters: 5:30pm - 7:00pm

Session Location: Georgia World Congress Center, Exhibit Hall A

Poster Number: 36-LB-P

Presentation Title

Four-year Modeled Incidence of Type 2 Diabetes Simulating the Metabolic Profile of Patients Pre- or Post- Treatment With Phentermine and Topiramate Extended-Release

Authors:  James Li, MD a; Nancy L. Reaven, MA b; Susan E. Funk, MBA b; Karen McGaughey, PhD c; Martin Neovius, PhD d

Affiliations:   aMiles Memorial Hospital, Damariscotta, Maine, USA; bStrategic Health Resources, La Canada, CA, USA; cCalifornia Polytechnic State University, San Luis Obispo, CA, USA; dKarolinska Institute, Stockholm, Sweden

Date/Time

Poster Presentation Date: November 14, 2013
  • Poster viewing: 10:00am - 3:30pm and 5:30pm - 7:00pm
  • Authors present posters: 5:30pm - 7:00pm

Session Location: Georgia World Congress Center, Exhibit Hall A

Poster Number: 35-LB-P

Presentation Title

Four-Year Healthcare Cost Simulation Matching Metabolic Profiles of Patients Pre- or Post-Treatment with Phentermine and Topiramate Extended-Release

Authors: James Li, MD a; Nancy L. Reaven, MA b; Susan E. Funk, MBA b; Karen McGaughey, PhD c; Martin Neovius, PhD d

Affiliations: aMiles Memorial Hospital, Damariscotta, Maine, USA; bStrategic Health Resources, La Canada, CA, USA; cCalifornia Polytechnic State University, San Luis Obispo, CA, USA; dKarolinska Institute, Stockholm, Sweden

Date/Time

Poster Presentation Date: November 14, 2013
  • Poster viewing: 10:00am - 3:30pm and 5:30pm - 7:00pm
  • Authors present posters: 5:30pm - 7:00pm

Session Location: Georgia World Congress Center, Exhibit Hall A

Poster Number: 34-LB-P

Presentation Title

Effects of Phentermine and Topiramate Extended-Release on Weight Loss and Obstructive Sleep Apnea

Authors: David H. Winslow, MD a; Charles H. Bowden, MD b; Karen DiDonato, RN, MSN b; Pamela A. McCullough, PhD a

Affiliations: aKentucky Research Group, Louisville, KY; bVIVUS, Inc., Mountain View, CA

Date/Time

Poster Presentation Date: November 15, 2013
  • Poster viewing: 10:00am-3:30pm
  • Authors present posters: 12:00pm-1:30pm

Session Location: Georgia World Congress Center, Exhibit Hall A

Poster Number: T-747-P

Presentation Title

Effects of Phentermine and Topiramate Extended-Release on Weight Loss and Glycemia When Stratified by Baseline Body-Mass Index Over 1 Year

Authors: Timothy Church, MD, MPH, PhD a; Wesley W. Day, PhD b

Affiliations: aPennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA; bVIVUS, Inc., Mountain View, CA

Date/Time

Poster Presentation Date: November 15, 2013
  • Poster viewing: 10:00am-3:30pm
  • Authors present posters: 12:00pm-1:30pm

Session Location: Georgia World Congress Center, Exhibit Hall A

Poster Number: T-743-P

Presentation Title

Effects of Phentermine and Topiramate Extended-Release Treatment on Weight Loss by Gender, Age, Race, or Ethnicity Over 1 Year

Authors: Donna Ryan, MD a; Santosh T. Varghese, MD b

Affiliations: aPennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA; bVIVUS, Inc., Mountain View, CA

Date/Time

Poster Presentation Date: November 15, 2013
  • Poster viewing: 10:00am-3:30pm
  • Authors present posters: 12:00pm-1:30pm

Session Location: Georgia World Congress Center, Exhibit Hall A

Poster Number: T-744-P

Presentation Title

Cost of Completing 1 Year of Treatment With Phentermine and Topiramate Extended-release in an Overweight and Obese Population

Authors: Erin Zagadailov, PharmD, MS a; Tommy Bramley, RPh, PhD a; Rashad Carlton, PharmD, MSPH a; Sunil Karnawat, PhD b; Weiyu Liu, MHA b

Affiliations: aXcenda, Palm Harbor, FL; bVIVUS, Inc., Mountain View, CA

About Qsymia

Qsymia ® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia ® (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.

The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ending December 31, 2012, as amended by the Form 10-K/A filed on April 30, 2013 and by the Form 10-K/A filed on June 12, 2013, and periodic reports filed with the Securities and Exchange Commission.
CONTACT: VIVUS, Inc.         Dana B. Shinbaum         Corporate Development & Investor Relations         shinbaum@vivus.com                  Investor Relations:         The Trout Group         Brian Korb         bkorb@troutgroup.com         646-378-2923